oncgnostics GmbH
General information
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena, Thuringia
Germany
Contact person: Alfred Hansel, Chief Executive Officer
Company main phone: +49 (3641) 5548500
Website: https://www.oncgnostics.com
Löbstedter Str. 41
07749 Jena, Thuringia
Germany
Contact person: Alfred Hansel, Chief Executive Officer
Company main phone: +49 (3641) 5548500
Website: https://www.oncgnostics.com
| Year founded: | 2012 |
| Source of foundation: | Spin-off from public institution / NPO |
| Name of foundation source: | University women's hospital, Jena |
Corporate description / mission:
oncgnostics GmbH is specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics. The company's products are cancer tests that detect characteristic epigenetic changes, i.e. DNA methylations, in cancer cells. These highly informative biomarkers, which they have identified and patented, are the basis of research and development for further IVD tests. The company's GynTect® enables the simple and reliable detection of methylated DNA regions in cervical scrapes. Methylation of GynTect® biomarkers occurs specifically in cervical cancer or its precursors, but not in samples from healthy women. Thus, GynTect® can help to clarify whether there is already a tissue alteration that needs to be treated.
oncgnostics GmbH is specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics. The company's products are cancer tests that detect characteristic epigenetic changes, i.e. DNA methylations, in cancer cells. These highly informative biomarkers, which they have identified and patented, are the basis of research and development for further IVD tests. The company's GynTect® enables the simple and reliable detection of methylated DNA regions in cervical scrapes. Methylation of GynTect® biomarkers occurs specifically in cervical cancer or its precursors, but not in samples from healthy women. Thus, GynTect® can help to clarify whether there is already a tissue alteration that needs to be treated.
State of ownership: Private / independent
Headquarters: HQ: Yes
Headquarters: HQ: Yes
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Description of products:
GynTect® – assay for cervical cancer screening
The company is developing tests based on DNA methylation markers that detect cancer cells in the patient’s saliva.
The company is also developing patient-friendly screening test could help to significantly reduce the number of deaths caused by ovarian cancer.
GynTect® – assay for cervical cancer screening
The company is developing tests based on DNA methylation markers that detect cancer cells in the patient’s saliva.
The company is also developing patient-friendly screening test could help to significantly reduce the number of deaths caused by ovarian cancer.
© 2024 Biotechgate by Venture Valuation